Immunoinformatics Insights into the Internalin A and B Proteins to Design a Multi-Epitope Subunit Vaccine for L. monocytogenes

Asadollahi, Parisa; Pakzad, Iraj; Sadeghifard, Nourkhoda; Ghafourian, Sobhan; Kazemian, Hossein; Kaviar, Vahab Hassan; Fattahi, Roohollah; Kalani, Behrooz Sadeghi

doi:10.1007/s10989-021-10359-w

Cited by 8 publications

(2 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…All selected epitopes need to be evaluated for their antigenicity, allergenicity, and toxicity 63 . To assess antigenicity, the VaxiJen online web server ( http://www.ddg-pharmfac.net/Vaxijen/VaxiJen/VaxiJen.html ) was performed with the bacteria parameter and a threshold of 0.4 were selected.…”

Section: Methodsmentioning

confidence: 99%

In silico designed novel multi-epitope mRNA vaccines against Brucella by targeting extracellular protein BtuB and LptD

Shi,

Zhu,

Yin

et al. 2024

Sci Rep

View full text Add to dashboard Cite

Brucella, a gram-negative intracellular bacterium, causing Brucellosis, a zoonotic disease with a range of clinical manifestations, from asymptomatic to fever, fatigue, loss of appetite, joint and muscle pain, and back pain, severe patients have developed serious diseases affecting various organs. The mRNA vaccine is an innovative type of vaccine that is anticipated to supplant traditional vaccines. It is widely utilized for preventing viral infections and for tumor immunotherapy. However, research regarding its effectiveness in preventing bacterial infections is limited. In this study, we analyzed the epitopes of two proteins of brucella, the TonB-dependent outer membrane receptor BtuB and the LPS assembly protein LptD, which is involved in nutrient transport and LPS synthesis in Brucella. In order to effectively stimulate cellular and humoral immunity, we utilize a range of immunoinformatics tools such as VaxiJen, AllergenFPv.1.0 and SignalP 5.0 to design proteins. Finally, five cytotoxic T lymphocyte (CTL) cell epitopes, ten helper T lymphocyte (HTL) cell epitopes, and eight B cell epitopes were selected to construct the vaccine. Computer simulations are also used to verify the immune response of the vaccine. The codon optimization, in silico cloning showed that the vaccine can efficiently transcript and translate in E. coli. The secondary structure of mRNA vaccines and the secondary and tertiary structures of vaccine peptides were predicted and then docked with TLR-4. Finally, the stability of the developed vaccine was confirmed through molecular dynamics simulation. These analyses showed that the design the multi-epitope mRNA vaccine could potentially target extracellular protein of prevalent Brucella, which provided novel strategies for developing the vaccine.

show abstract

Section: Methodsmentioning

confidence: 99%

In silico designed novel multi-epitope mRNA vaccines against Brucella by targeting extracellular protein BtuB and LptD

Shi,

Zhu,

Yin

et al. 2024

Sci Rep

View full text Add to dashboard Cite

show abstract

“…Unfortunately, peptide-based vaccines have a low immunogenicity index, and DNA vaccines carry the risk of insertional mutagenesis into the host’s DNA. On the other hand, mRNA vaccines are more efficient, addressing the safety and efficacy concerns that arise with DNA and peptide-based vaccines [ 15 , 16 ]. In addition, cell-free mRNA vaccines can be produced quickly, cost-effectively and at scale.…”

Section: Introductionmentioning

confidence: 99%

Development of innovative multi-epitope mRNA vaccine against Pseudomonas aeruginosa using in silico approaches

Asadinezhad,

Khoshnood,

Asadollahi

et al. 2023

Briefings in Bioinformatics

Self Cite

View full text Add to dashboard Cite

The rising issue of antibiotic resistance has made treating Pseudomonas aeruginosa infections increasingly challenging. Therefore, vaccines have emerged as a viable alternative to antibiotics for preventing P. aeruginosa infections in susceptible individuals. With its superior accuracy, high efficiency in stimulating cellular and humoral immune responses, and low cost, mRNA vaccine technology is quickly replacing traditional methods. This study aimed to design a novel mRNA vaccine by using in silico approaches against P. aeruginosa. The research team identified five surface and antigenic proteins and selected their appropriate epitopes with immunoinformatic tools. These epitopes were then examined for toxicity, allergenicity and homology. The researchers also checked their presentation and identification by major histocompatibility complex cells and other immune cells through valuable tools like molecular docking. They subsequently modeled a multi-epitope protein and optimized it. The mRNA was analyzed in terms of structure and stability, after which the immune system’s response against the new vaccine was simulated. The results indicated that the designed mRNA construct could be an effective and promising vaccine that requires laboratory and clinical trials.

show abstract

Novel toxin-based mRNA vaccine against Clostridium perfringens using in silico approaches

Asadollahi,

Kalani

2024

Toxicon

View full text Add to dashboard Cite

Immunoinformatics Insights into the Internalin A and B Proteins to Design a Multi-Epitope Subunit Vaccine for L. monocytogenes

Cited by 8 publications

References 22 publications

In silico designed novel multi-epitope mRNA vaccines against Brucella by targeting extracellular protein BtuB and LptD

In silico designed novel multi-epitope mRNA vaccines against Brucella by targeting extracellular protein BtuB and LptD

Development of innovative multi-epitope mRNA vaccine against Pseudomonas aeruginosa using in silico approaches

Novel toxin-based mRNA vaccine against Clostridium perfringens using in silico approaches

Contact Info

Product

Resources

About